Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Eaton

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Urology Reports|June 27, 2002
The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasiaG M Oades, J D Eaton, R S Kirby
BJU International|March 17, 2001
Urethral wands for impotenceS R Bott, J D Eaton, R S Kirby
Prostate Cancer and Prostatic Diseases|December 24, 2002
The role of adenoviral vectors in genetic prodrug activation therapy in prostate cancerJ D Eaton, I A Clarke, H Pandha, et al.
BJU International|February 19, 2002
Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancerJ D Eaton, M J A Perry, S Nicholson, et al.
Hematology (Amsterdam, Netherlands)|May 15, 2003
Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF)M Kaleelrahman, J D Eaton, D Leeming, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
The immunotherapy of prostate cancerA G Dalgleish, M J A Perry, J D Eaton, et al.
Gene Therapy|April 25, 2001
Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniquesJ D Eaton, M J Perry, S M Todryk, et al.
British Journal of Haematology|February 13, 2001
Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use studyR Chopra, J D Eaton, A Grassi, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Urology Reports|June 27, 2002
The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasiaG M Oades, J D Eaton, R S Kirby
BJU International|March 17, 2001
Urethral wands for impotenceS R Bott, J D Eaton, R S Kirby
Prostate Cancer and Prostatic Diseases|December 24, 2002
The role of adenoviral vectors in genetic prodrug activation therapy in prostate cancerJ D Eaton, I A Clarke, H Pandha, et al.
BJU International|February 19, 2002
Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancerJ D Eaton, M J A Perry, S Nicholson, et al.
Hematology (Amsterdam, Netherlands)|May 15, 2003
Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF)M Kaleelrahman, J D Eaton, D Leeming, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
The immunotherapy of prostate cancerA G Dalgleish, M J A Perry, J D Eaton, et al.
Gene Therapy|April 25, 2001
Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniquesJ D Eaton, M J Perry, S M Todryk, et al.
British Journal of Haematology|February 13, 2001
Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use studyR Chopra, J D Eaton, A Grassi, et al.
Pageof 1